Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.55 |
| ▸ | MMP2 | P08253 | 4/20 | 0.53 |
| ▸ | ALPI | P09923 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | XIAP | P98170 | 1/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SCN4A | P35499 | 2/20 | 0.49 |
| ▸ | ANPEP | P15144 | 1/20 | 0.48 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Solriamfetol SCHEMBL42526 | 1.00 | PKM (0.56) | PKMCYP1A2CYP2D6SMN1; SMN2NPSR1 | |
| Solriamfetol SCHEMBL2739637 | 1.00 | PKM (0.56) | PKMCYP1A2CYP2D6SMN1; SMN2NPSR1 | |
| Solriamfetol SCHEMBL30929348 | 1.00 | PKM (0.56) | PKMCYP1A2CYP2D6SMN1; SMN2NPSR1 | |
| Solriamfetol SCHEMBL30929349 | 1.00 | PKM (0.56) | PKMCYP1A2CYP2D6SMN1; SMN2NPSR1 | |
| Solriamfetol SCHEMBL8430382 | 0.98 | PKM (0.54) | PKMCYP1A2CYP2D6SMN1; SMN2NPSR1 | |
| Solriamfetol SCHEMBL28413501 | 0.98 | PKM (0.54) | PKMCYP1A2CYP2D6SMN1; SMN2NPSR1 | |
| Solriamfetol SCHEMBL4987496 | 0.98 | PKM (0.54) | PKMCYP1A2CYP2D6SMN1; SMN2NPSR1 | |
| Solriamfetol SCHEMBL8426383 | 0.98 | PKM (0.54) | PKMCYP1A2CYP2D6SMN1; SMN2NPSR1 | |
| Solriamfetol SCHEMBL30518836 | 0.97 | PKM (0.53) | PKMCYP1A2CYP2D6SMN1; SMN2NPSR1 | |
| Solriamfetol SCHEMBL30518840 | 0.95 | PKM (0.51) | PKMCYP1A2CYP2D6SMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 211 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239740-A1 | TREATMENT OF SLEEP-WAKE DISORDERS | SK BIOPHARMACEUTICALS CO LTD (KR) | 2024-07-18 | — | — | US | claimed |
| US-20230278950-A1 | METHODS FOR TREATING ATTENTION-DEFICIT/HYPERACTIVITY DISORDER | SK BIOPHARMACEUTICALS CO LTD (KR) | 2023-09-07 | — | — | US | claimed |
| US-11524935-B2 | Methods for treating attention-deficit/hyperactivity disorder | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2022-12-13 | — | — | US | claimed |
| US-20210078943-A1 | TREATMENT OF SLEEP-WAKE DISORDERS | SK BIOPHARMACEUTICALS CO LTD (KR) | 2021-03-18 | — | — | US | claimed |
| US-20210070694-A1 | METHODS FOR TREATING ATTENTION-DEFICIT/HYPERACTIVITY DISORDER | SK BIOPHARMACEUTICALS CO LTD (KR) | 2021-03-11 | — | — | US | claimed |
| EP-3552604-B1 | COMPOSITIONS FOR TREATING DRUG ADDICTION AND IMPROVING ADDICTION-RELATED BEHAVIOR | SK BIOPHARMACEUTICALS CO LTD (KR) | 2020-12-16 | — | — | EP | claimed |
| EP-3552604-A1 | COMPOSITIONS FOR TREATING DRUG ADDICTION AND IMPROVING ADDICTION-RELATED BEHAVIOR | SK Biopharmaceuticals Co., Ltd. (KR) | 2019-10-16 | — | — | EP | claimed |
| US-20190194125-A1 | METHODS FOR TREATING ATTENTION-DEFICIT/HYPERACTIVITY DISORDER | SK BIOPHARMACEUTICALS CO LTD (KR) | 2019-06-27 | — | — | US | claimed |
| EP-3308785-A2 | USE OF FLECAINIDE AS AN ANTI-CONNEXIN AGENT AND METHOD FOR POTENTIATING THE EFFECTS OF A PSYCHOTROPIC DRUG | Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) | 2018-04-18 | — | — | EP | claimed |
| US-20170355668-A1 | METHODS FOR TREATING ATTENTION-DEFICIT/HYPERACTIVITY DISORDER | SK BIOPHARMACEUTICALS CO LTD (KR) | 2017-12-14 | — | — | US | claimed |
| EP-1890684-A1 | TREATMENT OF SLEEP-WAKE DISORDERS | SK Holdings Co., Ltd. (KR) | 2008-02-27 | — | — | EP | claimed |
| WO-2006133393-A1 | TREATMENT OF SLEEP-WAKE DISORDERS | SK HOLDINGS CO., LTD. (KR) | 2006-12-14 | — | — | WO | claimed |
| EP-0873308-B1 | O-CARBAMOYL-PHENYLALANINOL COMPOUNDS AND THEIR PHARMACEUTICALLY USEFUL SALTS | SK CORP (KR) | 2002-01-02 | — | — | EP | claimed |
| EP-0820438-B1 | O-CARBAMOYL-PHENYLALANINOL HAVING SUBSTITUENT AT BENZENE RING, ITS PHARMACEUTICALLY USEFUL SALTS AND METHOD FOR PREPARING THE SAME | SK CORP (KR) | 2001-06-20 | — | — | EP | claimed |
| US-6140532-A | O-carbamoyl-phenylalaninol having substituent at benzene ring, its pharmaceutically useful salts and method for preparing the same | SK CORPORATION (US) | 2000-10-31 | — | — | US | claimed |
| EP-0873308-A1 | O-CARBAMOYL-PHENYLALANINOL COMPOUNDS, THEIR PHARMACEUTICALLY USEFUL SALTS AND PROCESS FOR PREPARING THE SAME | SK Corporation (KR) | 1998-10-28 | — | — | EP | claimed |
| US-5756817-A | TREATMENT OF DISEASES OF CENTRAL NERVOUS SYSTEMS | YUKONG LIMITED (KR) | 1998-05-26 | — | — | US | claimed |
| WO-1998015526-A1 | O-CARBAMOYL-PHENYLALANINOL COMPOUNDS, THEIR PHARMACEUTICALLY USEFUL SALTS AND PROCESS FOR PREPARING THE SAME | SK CORPORATION (KR) | 1998-04-16 | — | — | WO | claimed |
| EP-0820438-A1 | O-CARBAMOYL-PHENYLALANINOL HAVING SUBSTITUENT AT BENZENE RING, ITS PHARMACEUTICALLY USEFUL SALTS AND METHOD FOR PREPARING THE SAME | YUKONG LIMITED (KR) | 1998-01-28 | — | — | EP | claimed |
| WO-1996032375-A1 | O-CARBAMOYL-PHENYLALANINOL HAVING SUBSTITUENT AT BENZENE RING, ITS PHARMACEUTICALLY USEFUL SALTS AND METHOD FOR PREPARING THE SAME | YUKONG LIMITED (KR) | 1996-10-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070694-A1 | METHODS FOR TREATING ATTENTION-DEFICIT/HYPERACTIVITY DISORDER | CHAT, SLC6A3, SLC6A2 | PKM 3986/4885CYP1A2 1712/4885CYP2D6 1271/4885 |
| US-11524935-B2 | Methods for treating attention-deficit/hyperactivity disorder | CHAT, SLC6A3, SLC6A2 | PKM 3986/4885CYP1A2 1712/4885CYP2D6 1271/4885 |
| US-20230278950-A1 | METHODS FOR TREATING ATTENTION-DEFICIT/HYPERACTIVITY DISORDER | CHAT, SLC6A3, SLC6A2 | PKM 3986/4885CYP1A2 1712/4885CYP2D6 1271/4885 |
| US-20240239740-A1 | TREATMENT OF SLEEP-WAKE DISORDERS | HCRTR1, HCRTR2, MTNR1B | PKM 3390/4885CYP1A2 119/4885CYP2D6 264/4885 |
| US-20210078943-A1 | TREATMENT OF SLEEP-WAKE DISORDERS | HCRTR1, HCRTR2, MTNR1B | PKM 3390/4885CYP1A2 119/4885CYP2D6 264/4885 |
| US-20170355668-A1 | METHODS FOR TREATING ATTENTION-DEFICIT/HYPERACTIVITY DISORDER | CHAT, SLC6A3, SLC6A2 | PKM 3986/4885CYP1A2 1712/4885CYP2D6 1271/4885 |
| US-20190194125-A1 | METHODS FOR TREATING ATTENTION-DEFICIT/HYPERACTIVITY DISORDER | CHAT, SLC6A3, SLC6A2 | PKM 3986/4885CYP1A2 1712/4885CYP2D6 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.